128. By the end of 2011, Lonza was negotiating to sell one of its biotech facilities to a Chinese company for Seven Hundred Fifty Million Dollars ($750,000,000.00). However, the Chinese company insisted that Lonza license to it the PermaDerm Know-How technology and the marketing and distribution rights held by Regenicin. 129. Approval of PermaDerm for commercial use in China would have occurred immediately upon or shortly after consummation of the Lonza biotech facility sale to the Chinese company

http://www.regenicin.com/news/complaint_2013_09_30.pdf

Makes you wonder with the explosion recently in China if Amarantus is reaching out..

Gerald tweet 8/12/15:
Tragic situation in China. ESS needs to be brought to market worldwide to help save lives